According to a joint statement from Apollo Hospitals and Dr. Reddy’s Laboratories, Russia’s Sputnik V COVID-19 vaccine, which is identified as a third choice on the Cowin site and Aarogya Setu app, was administered today in a soft launch in Hyderabad that will be scaled up in the coming days.
Sputnik V joins Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin in the immunization program, which has been hampered in recent weeks by a vaccine shortage.
According to the joint statement, the exercise in Hyderabad will be followed by one in Visakhapatnam on Tuesday.
The vaccines will be administered in accordance with government-recommended SOPs, which would include registration on CoWIN.Dr. Reddy’s Laboratories’ Sputnik V was approved for use in India on April 12, 2021, with an emergency use authorization.
“Dr. Reddy’s and Apollo will use this pilot phase to test the arrangements and cold chain logistics, as well as prepare for the launch. We are optimistic that with the Sputnik V vaccine, we will be able to make a major contribution to improving COVID vaccine availability and affordability for the general public “Dr. K Hari Prasad, President of Apollo Hospitals’ Hospitals Division, said.
The pilot program will be expanded to Delhi, Mumbai, Bangalore, Ahmedabad, Chennai, Kolkata, and Pune after Hyderabad and Visakhapatnam, according to the announcement.
“As part of our soft pilot launch of the Sputnik V vaccine in India, we are pleased to work with Apollo Hospitals. We’re working to expand the pilot and get the vaccine to more cities, with the aim of inoculating as many Indians as possible in the coming months “Dr. Reddy’s Laboratories’ CEO, Branded Markets (India & Emerging Markets), MV Ramana, said.
The first batch of 1,50,000 vaccines arrived in Hyderabad on May 1 and will be included in the pilot project. On May 13, they were approved for use. India got the second consignment of Sputnik V on Sunday.
“Sputnik V’s effectiveness is well-known in the world. Since the second half of 2020, it has been successfully used to vaccinate people in Russia. It is also successful against the current COVID-19 strains, according to Russian experts “Nikolay Kudashev, Russia’s ambassador to India, said on Sunday.
Sputnik V has a 91.6 percent efficacy rate. The vaccine has been provided to over 2 crore people in 60 countries. Sputnik compares “very, very favorably” to other global vaccines in real-world data, and is among the top two or three.